drugset / Trial / NCT01572597

Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy

NCT01572597

Phase 4 Unknown 120 enrolled Buddhist Tzu Chi General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for re-eradication for gastric Helicobacter pylori infection.

Timeline

Start
2011-06
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metronidazole Small molecule 500 mg
Subject N-acetylcystein Unknown 600 mg
Background Amoxicillin Other / unclassified 1000 mg
Background Clarithromycin Small molecule 500 mg
Background Rabeprazole Small molecule 20 mg